Effects of eszopiclone on safety, subjective measures of efficacy, and quality of life in elderly and nonelderly Japanese patients with chronic insomnia, both with and without comorbid psychiatric disorders: a 24-week, randomized, double-blind study

Annals of General Psychiatry

Volumn 11, Issue , 2012, Pages

  Uchimura, Naohisa ^a   Kamijo, Atsushi ^b   Takase, Takao ^b  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b EISAI CO LTD   (Japan)

Author keywords

Elderly; Eszopiclone; Insomnia; Japanese; Long term; Psychiatric disorder; Quality of life

Indexed keywords

ESZOPICLONE;

ADULT; AGED; ARTICLE; BACKACHE; CHRONIC INSOMNIA; COMORBIDITY; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DAYTIME SOMNOLENCE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; DYSGEUSIA; ELECTROCARDIOGRAM; FEMALE; FUNCTIONAL STATUS; GERIATRIC PATIENT; GLUCOSE URINE LEVEL; HUMAN; INSOMNIA; JAPANESE; LONG TERM CARE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MULTICENTER STUDY; PATIENT COMPLIANCE; PHARYNGITIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SELF REPORT; SHORT FORM 36; SIDE EFFECT; SLEEP; SLEEP QUALITY; SLEEP TIME; SOMNOLENCE; THIRST; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; VITAL SIGN; WAKEFULNESS;

EID: 84862622433     PISSN: None     EISSN: 1744859X     Source Type: Journal    
DOI: 10.1186/1744-859X-11-15     Document Type: Article

References (26)

1. Roth T. Insomnia: definition, prevalence, etiology, and consequences. J Clin Sleep Med 2007, 3(5 Suppl):S7-S10. 1978319, 17824495.
2. State-of-the-Science Conference Statement on manifestations and management of chronic insomnia in adults. NIH Consens Sci Statements 2005, 22:1-30.
3. Doi Y. Epidemiologic research on insomnia in the general Japanese populations. Nihon Rinsho 2009, 67:1463-1467.
4. Neubauer DN. The evolution and development of insomnia pharmacotherapies. J Clin Sleep Med 2007, 3(5 Suppl):S11-S15. 1978321, 17824496.
5. Hartikainen S, Lönnroos E, Louhivuori K. Medication as a risk factor for falls: Critical systematic review. J Gerontol A Biol Sci Med Sci 2007, 62:1172-1181. 10.1093/gerona/62.10.1172, 17921433.
6. Owen RT. Eszopiclone: an update on its use in insomnia. Drugs Today 2011, 47:263-275.
7. Nutt DJ, Stahl SM. Searching for perfect sleep: the continuing evolution of GABAA receptor modulators as hypnotics. J Psychopharmacol 2010, 24:1601-1612. 10.1177/0269881109106927, 19942638.
8. Lunesta® (eszopiclone) tablets 1 mg, 2 mg, 3 mg: US prescribing information. 2010, Sunovion Pharmaceuticals Inc, Marlborough, MA, USA.
9. Zammit GK, McNabb LJ, Caron J, Amato DA, Roth T. Efficacy and safety of eszopiclone across 6-weeks of treatment for primary insomnia. Curr Med Res Opin 2004, 20:1979-1991. 10.1185/174234304X15174, 15701215.
10. Krystal AD, Walsh JK, Laska E, Caron J, Amato DA, Wessel TC, Roth T. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia. Sleep 2003, 26:793-799.
11. Erman MK, Zammit G, Rubens R, Schaefer K, Wessel T, Amato D, Caron J, Walsh JK. A polysomnographic placebo-controlled evaluation of the efficacy and safety of eszopiclone relative to placebo and zolpidem in the treatment of primary insomnia. J Clin Sleep Med 2008, 4:229-234. 2546455, 18595435.
12. McCall WV, Erman M, Krystal AD, Rosenberg R, Scharf M, Zammit GK. A polysomnography study of eszopiclone in elderly patients with insomnia. Curr Med Res Opin 2006, 22:1633-1642. 10.1185/030079906X112741, 16968566.
13. Scharf M, Erman M, Rosenberg R, Seiden D, McCall V, Amato D, Wessel TC. A 2-week efficacy and safety study of eszopiclone in elderly patients with primary insomnia. Sleep 2005, 28:720-727.
14. Foley D, Ancoli-Israel S, Britz P, Walsh J. Sleep disturbances and chronic disease in older adults: results of the 2003 National Sleep Foundation Sleep in America Survey. J Psychosom Res 2004, 56:497-502. 10.1016/j.jpsychores.2004.02.010, 15172205.
15. Ancoli-Israel S, Krystal AD, McCall WV, Schaefer K, Wilson A, Claus R, Rubens R, Roth T. A 12-week, randomized, double-blind, placebo-controlled study evaluating the effect of eszopiclone 2 mg on sleep/wake function in older adults with primary and comorbid insomnia. Sleep 2010, 33:225-234. 2817909, 20175406.
16. Walsh JK, Krystal AD, Amato DA, Rubens R, Caron J, Wessel TC, Schaefer K, Roach J, Wallenstein G, Roth T. Nightly treatment of primary insomnia with eszopiclone for six months: effect on sleep, quality of life, and work limitations. Sleep 2007, 30:959-968. 1978384, 17702264.
17. Roth T, Walsh JK, Krystal A, Wessel T, Roehrs TA. An evaluation of the efficacy and safety of eszopiclone over 12 months in patients with chronic primary insomnia. Sleep Med 2005, 6:487-495. 10.1016/j.sleep.2005.06.004, 16230048.
18. McCall WV, Blocker JN, D'Agostino R, Kimball J, Boggs N, Lasater B, Haskett R, Krystal A, McDonald WM, Rosenquist PB. Treatment of insomnia in depressed insomniacs: effects on health-related quality of life, objective and self-reported sleep, and depression. J Clin Sleep Med 2010, 6:322-329. 2919661, 20726279.
19. Fava M, McCall WV, Krystal A, Wessel T, Rubens R, Caron J, Amato D, Roth T. Eszopiclone co-administered with fluoxetine in patients with insomnia coexisting with major depressive disorder. Biol Psychiatry 2006, 59:1052-1060. 10.1016/j.biopsych.2006.01.016, 16581036.
20. Pollack M, Kinrys G, Krystal A, McCall WV, Roth R, Schaefer K, Rubens R, Roach J, Huang H, Krishnan R. Eszopiclone coadministered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder. Arch Gen Psychiatry 2008, 65:551-562. 10.1001/archpsyc.65.5.551, 18458207.
21. Diagnostic and statistical manual of mental disorders, 4th edition, text revision (DSM-IV-TR) 2000, American Psychiatric Press, Inc., Washington, DC.
22. Kurihara M, Jimbo M, Hirose T, Asano J, Endo S, Fujiya Y, Hada H, Haga M, Hasue I, Higuchi T, Karasumi H, Motomura H, Naito T, Nakamura R, Nakauchi M, Narita S, Noguchi T, Oyama K, Okada M, Okazaki Y, Sasaki K, Takahashi K, Takei H, Takeyama K, Watanabe J. Double-blind comparison of clinical effects of ID 540 (fludiazepam) diazepam and placebo on psychoneurotic patients and a tentative draft of dependency questionnaire [Japanese]. Rinsho Hyoka (Clinical Evaluation) 1977, 5:341-368.
23. Ohayon MM, Roth T. Place of chronic insomnia in the course of depressive and anxiety disorders. J Psychiatr Res 2003, 37:9-15. 10.1016/S0022-3956(02)00052-3, 12482465.
24. Roth T, Jaeger S, Jin R, Kalsekar A, Stang PE, Kessler RC. Sleep problems, comorbid mental disorders, and role functioning in the national comorbidity survey replication. Biol Psychiatry 2006, 60:1364-1371. 10.1016/j.biopsych.2006.05.039, 1894656, 16952333.
25. Neckelmann D, Mykletun A, Dahl AA. Chronic insomnia as a risk factor for developing anxiety and depression. Sleep 2007, 30:873-880. 1978360, 17682658.
26. Buysse DJ, Angst J, Gamma A, Ajdacic V, Eich D, Rössler W. Prevalence, course, and comorbidity of insomnia and depression in young adults. Sleep 2008, 31:473-480. 2279748, 18457234.